---
title: "Ohara Pharmaceutical"
description: "Ohara Pharmaceutical Co., Ltd. is a Japanese pharmaceutical manufacturer that develops and supplies orphan drugs and generic medicines. According to its official English website, the company focuses on responding to the needs of patients and medical professionals by providing high quality, affordable treatments and specialized therapies. Location details and broader corporate structure are not stated in relation to its role as an investor in Africa, so they are not included here. In Africa, Ohara Pharmaceutical has an active investment track record in health technology between June 2023 and April 2025, committing a total of 39.6 million dollars across three funding rounds. The company has participated in a Series B round, a venture round that is not specified by stage, and another round categorized as Other, all focused on health tech. Its capital has been directed to Kenya and Nigeria, backing MYDAWA in Kenya and Helium Health in Nigeria, which provide digital tools, medicines, and healthcare essentials. Across these African deals, Ohara Pharmaceutical has invested alongside a network of international co investors that includes AAIC Investment, Creadev, Investment Fund for Developing Countries, Alta Semper Capital, IFU, LCY Chemical, Anne Wojcicki, Western Technology Investment, Capria Ventures, Angaza Capital, AXA Investment Managers, Flat World Partners, Global Ventures, and Tencent. This pattern highlights Ohara Pharmaceutical’s role as a strategic health sector investor working with established regional and global partners in African health technology."
canonical_url: "https://liners.com/investors/ohara-pharmaceutical"
markdown_url: "https://liners.com/investors/ohara-pharmaceutical.md"
type: "investor"
language: "en"
updated_at: "2026-09-08T03:02:10.315Z"
---

# Ohara Pharmaceutical

Ohara Pharmaceutical Co., Ltd. is a Japanese pharmaceutical manufacturer that develops and supplies orphan drugs and generic medicines. According to its official English website, the company focuses on responding to the needs of patients and medical professionals by providing high quality, affordable treatments and specialized therapies. Location details and broader corporate structure are not stated in relation to its role as an investor in Africa, so they are not included here. In Africa, Ohara Pharmaceutical has an active investment track record in health technology between June 2023 and April 2025, committing a total of 39.6 million dollars across three funding rounds. The company has participated in a Series B round, a venture round that is not specified by stage, and another round categorized as Other, all focused on health tech. Its capital has been directed to Kenya and Nigeria, backing MYDAWA in Kenya and Helium Health in Nigeria, which provide digital tools, medicines, and healthcare essentials. Across these African deals, Ohara Pharmaceutical has invested alongside a network of international co investors that includes AAIC Investment, Creadev, Investment Fund for Developing Countries, Alta Semper Capital, IFU, LCY Chemical, Anne Wojcicki, Western Technology Investment, Capria Ventures, Angaza Capital, AXA Investment Managers, Flat World Partners, Global Ventures, and Tencent. This pattern highlights Ohara Pharmaceutical’s role as a strategic health sector investor working with established regional and global partners in African health technology.

## Breadcrumbs

- [Investors](/investors)
- [Ohara Pharmaceutical](/investors/ohara-pharmaceutical)

## Summary

Ohara Pharmaceutical Co., Ltd. is a Japanese pharmaceutical manufacturer that develops and supplies orphan drugs and generic medicines. According to its official English website, the company focuses on responding to the needs of patients and medical professionals by providing high quality, affordable treatments and specialized therapies. Location details and broader corporate structure are not stated in relation to its role as an investor in Africa, so they are not included here. In Africa, Ohara Pharmaceutical has an active investment track record in health technology between June 2023 and April 2025, committing a total of 39.6 million dollars across three funding rounds. The company has participated in a Series B round, a venture round that is not specified by stage, and another round categorized as Other, all focused on health tech. Its capital has been directed to Kenya and Nigeria, backing MYDAWA in Kenya and Helium Health in Nigeria, which provide digital tools, medicines, and healthcare essentials. Across these African deals, Ohara Pharmaceutical has invested alongside a network of international co investors that includes AAIC Investment, Creadev, Investment Fund for Developing Countries, Alta Semper Capital, IFU, LCY Chemical, Anne Wojcicki, Western Technology Investment, Capria Ventures, Angaza Capital, AXA Investment Managers, Flat World Partners, Global Ventures, and Tencent. This pattern highlights Ohara Pharmaceutical’s role as a strategic health sector investor working with established regional and global partners in African health technology.

## Recorded investments

| Product | URL | Stage | Amount | Date |
| --- | --- | --- | --- | --- |
| MYDAWA | /mydawa | Other | 9600000 | 2025-04-01T00:00:00.000Z |
| MYDAWA | /mydawa | Venture (Round not Specified) |  | 2025-04-01T00:00:00.000Z |
| Helium Health | /helium-health | Series B | 30000000 | 2023-06-01T00:00:00.000Z |

## Related pages

- [All investors](/investors)
- [Funding rounds](/funding)

## Access and citation

- [Canonical HTML page](https://liners.com/investors/ohara-pharmaceutical)
- [Markdown route index](/sitemap.md)
- [Agent access guide](/llms.txt)